Ginkgo Bioworks HoldingsDNABW 63 EV-to-FCF is 0.00 as of Jun. 27, 2026. GuruFocus rates DNABW with a GF Score™ of 63/100. The stock has 6 warning signs investors should review. Among 333 Biotechnology companies, Ginkgo Bioworks Holdings ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ginkgo Bioworks Holdings's Enterprise Value is $0.00 Mil.
Ginkgo Bioworks Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-168.20 Mil. Therefore, Ginkgo Bioworks Holdings's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Ginkgo Bioworks Holdings's EV-to-FCF or its related term are showing as below:
DNABW'
s EV-to-FCF Range Over the Past 10 Years
Min: -78.39 Med: -4.44 Max: -0.04
Current: -4.2
During the past 7 years, the highest EV-to-FCF of Ginkgo Bioworks Holdings was -0.04. The lowest was -78.39. And the median was -4.44.
DNABW's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs DNABW: -4.20
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ginkgo Bioworks Holdings's PE Ratio (TTM) for today is calculated as:
Ginkgo Bioworks Holdings's share price for today is $0.0009.
Ginkgo Bioworks Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ginkgo Bioworks Holdings EV-to-FCF Related Terms
Ginkgo Bioworks Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's EV-to-FCF falls into.
Ginkgo Bioworks Holdings's current Enterprise Value is $0.00 Mil.
Ginkgo Bioworks Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-168.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings (DNABW) has a EV-to-FCF of 0.00 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ginkgo Bioworks Holdings and its competitors. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #999999 out of 333 companies in the Biotechnology industry.
Is Ginkgo Bioworks Holdings' EV-to-FCF too high?
Ginkgo Bioworks Holdings' current EV-to-FCF is 0.00. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' EV-to-FCF compare to CADL and CABA?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #999999 out of 333 companies for EV-to-FCF. This places Ginkgo Bioworks Holdings in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current EV-to-FCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Ginkgo Bioworks Holdings (DNABW) has a current EV-to-FCF of 0.00. The current EV-to-FCF is 0.00. Ginkgo Bioworks Holdings' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNABW), the current EV-to-FCF is 0.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
63GF Score
Get the complete analysis for DNABW
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNABW has been successfully added to your 
